Crystal structures of RidA, an important enzyme for the prevention of toxic side products

Xiwen Liu1,2, Jianhua Zeng1,2, Xiaolei Chen1,2 & Wei Xie1,2

The YjgF/YER057c/UK114 family proteins are highly conserved across all three domains of life, and most of them currently have no clearly defined biological roles. In vitro, these proteins were found to hydrolyze the enamine/imine intermediates generated from serine or threonine, and were renamed Reactive Intermediate Deaminase A (RidA). RidA was recently discovered in Arabidopsis thaliana, and by deaminating the toxic enamine/imine intermediates, it prevents the inactivation of many functionally important pyridoxal 5′-phosphate (PLP)-containing enzymes in plants such as branched-chain aminotransferase BCAT (IlvE). In this study, we determined the crystal structure of Arabidopsis thaliana RidA in the apo form, as well as RidA complexed with the ligand pyruvate. RidA forms the trimeric, barrel-like quaternary structure and inter-subunit cavities, and resembles most RidA family members. Each pyruvate molecule binds to the interface between two subunits, and the recognition of pyruvate is achieved by the interactions with R165 and T167. From sequence alignment and structural superposition, we identified a series of key residues responsible for the trimer assembly, whose importance was confirmed by enzymatic assays. This study provides structural insight into RidA functions in plants.

The YjgF/YER057c/UK114 proteins were named after proteins YjgF, YER057c, and UK114, which were found in Escherichia coli, yeast, and goat respectively. These small proteins (~15 kDa) are found across all three domains of life with a signature of 6–9 conserved amino acids, and to date, hundreds of putative members have been identified by bioinformatic analyses. They appear to play important roles in highly diverse biological processes, many of which are poorly understood despite their universal presence. Studies have suggested that they remove the reactive metabolites that could otherwise inhibit key metabolic enzymes. In bacteria and yeasts, YjgF/YER057c/UK114 proteins are associated with distinct pathways such as the isoleucine, thiamine, and purine biosynthesis. YjgF protein from Salmonella enterica was found to deaminate the enamine/imine intermediates generated by pyridoxal 5′-phosphate (PLP)-dependent serine/threonine dehydratases, and was renamed RidA (reactive intermediate/imine deaminase A). Not only can these enamine/imines inactivate PLP enzymes by acting on the PLP cofactor, but also they form Michael adducts with cysteines (reviewed by reference 11). Therefore the enamine/imine intermediates cause significant cellular damage if allowed to accumulate, and RidA is responsible for the clearance of these reactive species. Other RidA functions including Hsp90-like chaperone activity, ribonuclease activity, photosynthesis as well as chromoplastogenesis have also been reported.

In 2014, RidA proteins were identified in Arabidopsis thaliana and maize. Arabidopsis thaliana RidA (AtRidA) is targeted to chloroplasts. By converting the reactive enamine/imines to harmless 2-oxoacids, RidA preempts damage to BCAT3 and ensures that the isoleucine biosynthesis can proceed. A recent phylogenetic analysis suggested that RidA could be divided into seven subfamilies (Rid1 to Rid7) besides the archetypal RidA subfamily. These subfamilies are generally found in bacteria, and coexist with each other in the same organism including RidA. The Rid1 to Rid3 subfamilies contain a conserved arginine residue known to be essential for the imine-hydrolyzing activity in the archetypal RidA and Rid2 subfamilies. By contrast, the Rid4 to Rid7 subfamilies appear not to hydrolyze imines, and their functions are yet to be identified.

A few crystal structures have been reported for the YjgF family proteins (for example, PDB codes 1QD9, 1X25, 1QU9, 2UYN and 1ONJ). These proteins share similar homotrimeric biological structures, and they
display a barrel shape with a deep cavity in the trimer. Additionally, three clefs are formed at the interfaces of adjacent monomers, which are considered to be the putative ligand-binding sites. In 2007, the crystal structures of Escherichia coli TdcF in complexes with a variety of ligands including 2-oxobutanoate were solved, which provided great insight into the substrate recognition mechanism of RidA family of proteins. Low molecular-weight metabolites with a carboxylate group such as 2-oxobutanoate, propionate, serine, acetate, and benzoate are capable of binding at the clefs between the two monomers. The interactions with 2-oxobutanoate involve a bi-dentate salt bridge with R105, and the keto group makes two additional hydrogen bonds with C107 and E120 respectively.

In this study, we determined the crystal structures of apo-AtRidA and its complex with pyruvate, and analyzed its structural basis for ligand recognition. AtRidA retains the typical domain as observed in many other RidA members. Using sequence alignment and structural superposition methods, we identified critical residues for trimer assembly as well as catalysis, and their importance to enzyme functions was evaluated by size-exclusion chromatography analyses and enzymatic assays.

**Results and Discussion**

**Overall structure of apoenzyme and comparison with homologous proteins.** The N-terminus of RidA is predicted to harbor a disordered region, which may function as a transit peptide targeting RidA to chloroplasts. To obtain crystals of the apoenzyme, we created several constructs with different starting sites within the sequence. The current crystal structure was produced by the construct starting from S68 (named AtRidA-S68), and it diffracted to a resolution of 2.0 Å. In the final model, residues S80-L187, as well as 85 water molecules are resolved. The model displays good geometry, with 98.1% and 1.9% residues falling into the Ramachandran-favored and allowed regions respectively. Each asymmetric unit contains a single monomer, with a Matthews’s coefficient of 1.85 and an estimated solvent content of 33.7%. The model shows a mixed β-sheet packed against two long α-helices (Fig. 1B). In the β-sheet, the strands are antiparallel except for the outermost strand, which is parallel to it. An extended loop L91-E110 is located between β2 and α1.

A DALI search from the PDB database retrieves several close structural homologs for RidA, and they are the acid-soluble protein hp14.5 from Homo sapiens (PDB code 1NQ3) and the tumor associated antigen UK114 from Hapi (PDB code 1ONI), the tumor associated antigen UK114 from Hapi (PDB code 1NQ3), the putative translation initiation inhibitor PH0854 from Pyrococcus horikoshii (PDB code 2DYY, unpublished), and a putative endoribonuclease l-PSP from Entamoeba histolytica (PDB code 3M4S, unpublished) respectively. AtRidA-S68 shares ~54% sequence identity with its closest structural neighbor hp14.5, with a root-mean-square deviation (RMSD) of 0.71 Å over 107 Cα atoms (Fig. 1C,D). Additionally, AtRidA is highly similar to other RidA family members in structure, and their overall structures are conserved. The most obvious difference is that AtRidA lacks an extra antiparallel strand at the N-terminus.

**Trimer formation.** The space group of apo-AtRidA is H3 and through symmetry operation, a homotrimer can be generated. There is a central cavity in the barrel-like trimeric structure, whose height is ~31 Å (Fig. 2A). The inner side of the barrel is formed by the β-sheet from each monomer, and the bottom is sealed by the Q169-K178 loop. The α-helices pack on the outside of the barrel, while the β-strands are approximately parallel to the 3-fold crystallographic axis. The buried surface between the neighboring monomers is 1306.2 Å². A small fragment P99-T101 is at the distal end of the trimer structure, and has higher B-factors than other regions (Fig. 2A).

RidA exists as a homotrimer not only in crystals, but also in solution. The protein shows a peak at 10.7 ml on a Superdex-75 size-exclusion column and corresponds to a molecular weight of ~40 kDa, roughly the size of a trimer (Fig. 2B). From sequence alignment and structure superposition, we discovered that two invariant residues, K136 and E182, are critical for the interfacial interactions by forming a monodentate salt bridge (Fig. 2C). Additionally, E182 also makes a hydrogen bond with the highly conserved residue S166, further reinforcing the interactions between the neighboring monomers. Furthermore, two serine residues, S80 and S92 are involved in hydrogen-bonding interactions with the backbone nitrogens of S162 and R165 respectively. To test their contribution to the trimer assembly, we mutated these residues to Ala or Arg (S80A, S92A, K136A, K136R, S166A and E182A) by site-directed mutagenesis. All these mutations did not significantly reduce the stability of AtRidA except for the S92A mutant, which is prone to precipitation. Size-exclusion chromatography analyses showed that all these mutants have slower migration rates than that of WT, suggesting partial disruption of the trimer. K136R and S80A affect the interface the least, while K136A severely impacts the assembly, which underscores the indispensable role of the K136-E182 salt bridge as well as the inter-subunit hydrogen bonds in maintaining the oligomeric state (Fig. 2B).

**Complex structure with pyruvate.** In addition to the apoprotein structure, we also tried to obtain the complex structures of AtRidA as well, in order to further explore its ligand recognition mechanism. Threonine dehydrogenase is able to remove a water molecule from both serine and threonine to generate the imine intermediates, which are in turn converted to 2-oxoacids (2-oxobutanoate or pyruvate) by the deamination activities of RidA. The intermediates are highly unstable and have short lifetimes, which are unsuitable for crystallization. Therefore we tried both 2-oxoacid products for cocrystallization studies, and we obtained the complex structure of AtRidA bound by pyruvate.

The structure was obtained by soaking the crystals of the apoprotein with 20 mM pyruvate for 1 hour, and the resulting crystals diffracted to 2.3 Å. The crystals did not appear to have decayed, but the crystal space group became P1. After structure determination, we found that there were three monomers present in the asymmetric
Figure 1. The enzymatic pathway that RidA participates and its overall structure. (A) The metabolic pathway involving AtRidA. (B) The structure of the RidA monomer. The major secondary structural elements, the N-, and C-termini of RidA are labeled. The helices, strands and loops are colored in red, yellow and green respectively. (C) The structure overlay of RidA and structural homologs. AtRidA (PDB code 5HP7, green), Homo sapiens hp14.5 (PDB code 1ONI, magenta), Capra hircus UK114 from (PDB code 1NQ3, yellow), Pyrococcus horikoshii PH0854 (PDB code 2DYY, dirty violet), and Entamoeba histolytica l-PSP (PDB code 3M4S, gray) respectively. The extra strand present in other homologs is circled by the blue oval. (D) Multiple sequence alignment of RidA homologs as in (C). The secondary structure of RidA is drawn on the top. Identical residues in sequences are on a red background, and similar residues are in red. Critical residues involved in the trimer formation are indicated by the solid blue circles, while residues for ligand binding are represented by the solid red circles. R165 is indicated by the red arrow.
unit. In each monomer of the final model, residues S80-L187 are resolved without internal disorder. The three monomers within the asymmetric unit form the trimeric barrel, which is almost identical to that formed by the

Figure 2. The overall structure the RidA trimer. (A) Two orthogonal views of the trimer. One of the monomers is colored according to the regional B-factors of the protein. The fragment that has high B-factors is indicated by the circle. (B) The oligomeric states of the WT RidA and mutants as assessed by size-exclusion chromatography. 0.5 mg of RidA WT and mutants were loaded onto a Superdex-75 size-exclusion column separately. Protein standards were used as a size reference and their respective sizes are indicated by the numbers on the top of each peak (red trace, St. p). (C) The interaction network that maintains the trimer assembly from top view. The insets show close-up views of the interface and primes denote residues from the neighboring subunits. The possible hydrogen bonds and salt bridges are represented by the red dashed lines (cutoff distances are set to 3.3 Å).
Enzyme Assays. To assess the importance of individual residues to enzyme activities, we measured the activities of RidA and mutant proteins by monitoring the UV-absorbance of semicarbazones, which are the reaction products of semicarbazide with the imines. The deamination activity of RidA converts the imine intermediates to 2-oxoacids, which can be further reduced by lactate dehydrogenase in the presence of NADH. The reactions are started by threonine in the absence of RidA, at which time the synthesis of semicarbazones proceeds at the maximal rate (Fig. 4). The mutants we tested not only include the residues that are directly involved in substrate/product binding, but also the residues responsible for the trimer formation.

The addition of 10 μM RidA WT reduced semicarbazone formation over a time course of 150 s, where the initial velocity of the enzyme remains linear. By contrast, the mutations reduced the deamination rates by various degrees. R165A, K136A/R are among the mutations that caused the most reduction in enzymatic activities, implying that the deamination product binding, but also the residues responsible for the trimer formation.

Figure 3. The ligand recognition pattern by RidA. (A) The superposition of the trimer AtRidA structure with (orange) and without (violet) pyruvate. The pyruvate ligands are shown as the spheres. (B) The specific recognition of pyruvate by AtRidA; (C) and 2-oxobutanoate by TdcF (Hydrogen bond cutoff distances are set to 3.3 Å). The blue lines show the distances between the conserved glutamate and the ligand carbonyl groups.
addition, a complex with pyruvate suggests that R165 and T167 play key roles in the recognition of the carboxylate group, and may also be responsible for the recognition of the imine substrate using the same type of interactions. Lastly, through activity assays, we discovered that the trimeric state is equally important to enzymatic activities, to which K136 and R165 contribute the most. This study provides structural insight into RidA functions in plants.

**Experimental Procedures**

**Cloning, expression and purification of RidA.** The full-length *Arabidopsis thaliana* RidA gene (GenBank accession No. AY060547.1) was amplified from *Arabidopsis* cDNA. After double digestion by the NdeI and XhoI restriction enzymes, the PCR product was ligated into a modified pET-28a (+) vector (Novagen) vector with an engineered PreScission protease cleavage site (recognition peptide LEVLFQGP) preceding the His6-tag. For crystallization purposes, N-terminal truncated fragments with various lengths were cloned into pET-28a (+) using the same sites. The primers used in this study were shown in Table 1. These plasmids were transformed into the following E. coli strains: DH5α, BL21 (DE3), and Rosetta (DE3) (Novagen). The plasmids were sequenced (GenBank accession No. AY060547.1) before use and the transforant colonies were screened by 

**Table 1.** The primers used in this study. The restriction sites were underlined in the amplifying primers while the mutated bases were italized in the *Quikchange* primers.

| Name          | Sequence                                      |
|---------------|-----------------------------------------------|
| F-RidA-FL-NdeI | AATAGATTCTATATGACTTGGTCGGTTTTCAGA             |
| R-RidA-FL-XhoI | TTGCACTTCCTGACGCTAGAGGTTTGCTCAATACATCAAT     |
| F-RidA-S80A   | GCTTTGGGACCTTACGCTGAGGCCATTAAAG               |
| R-RidA-S80A   | CTTTTAATGGCCCTGAGCTAAGGTCCCAAAGGC            |
| F-RidA-S92A   | TCTGGTGTTCCTTACGAGTTTGCTTCTTGG               |
| R-RidA-S92A   | CCAAGAACACCTGCAAGAAAACCCAGA                  |
| F-RidA-K136R  | TCCTCGGTGGTGAGGACACAACTCATGT                 |
| R-RidA-K136R  | CATGATTGTGTCCCTACCCACCCGAGGA                 |
| F-RidA-K136A  | ATTCTCCTGTTGGGTAGCCGACCAACACACTGT            |
| R-RidA-K136A  | ACATGATTGTGTGGCCACCCGACCGGAAAT               |
| F-RidA-R165   | CTCCTTCTCCAGGACAGTGAGCTATCAAGA               |
| R-RidA-R165   | CTTGATACGTCGA7GCTGCTGAGAGAGAAGGAG            |
| F-RidA-S166A  | CCTTCTCCAGCAGCGCTGAGCAGCTATCAAGT            |
| R-RidA-S166A  | CAACCTTGATACGCTGCTGAGCTATCAAGT              |
| F-RidA-T167A  | CCACGACGATCCGAGTGATCAGTGTCCTTGG             |
| R-RidA-T167A  | CAACCTTGATACGCGATCAGTGTCCTTGG               |
| F-RidA-E180A  | AAACGCCAAGATCGCGATGAAATGATTGTG              |
| R-RidA-E180A  | CAAATACATTCAATCGCGATCTGCGCGGTT              |
| F-RidA-E182A  | CAAATCGAGATGTGAGCTATGAAATGCGCC              |
| R-RidA-E182A  | GTGTTGCAATACATGCAATCCTGATCTTGG              |

**Figure 4.** The enzymatic activity assays of WT RidA and mutants. The rate of semicarbazone (Sc) formation was measured by absorbance at 248 nm, and the assay mixtures contained 10 μM RidA WT and mutants. Semicarbazone formation is slowest in the presence of WT RidA because the enzyme removes most of the reactive imine before it has a chance to react with semicarbazide. Greater rates of semicarbazone formation are noted in the presence of the mutants because the mutant enzymes are unable to hydrolyze the imine as effectively as the WT enzyme.
the *Escherichia coli* strain BL21 (DE3) cells. To overexpress the protein, 10 ml overnight culture was used to inoculate 1 L fresh culture medium containing 30 μg/ml kanamycin and grown at 37 °C until the log phase was reached (OD600 = 0.8). The expression of RidA-S68 was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.2 mM, at 25 °C for 18 hours. Cells were harvested by centrifugation at 3,030 g for 20 min at 4 °C, and resuspended in pre-chilled nickel-nitrilotriacetic acid (Ni–NTA) buffer A (250 mM NaCl, 10 mM imidazole, 40 mM Tris-HCl, pH 8.0, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mM β-mercaptoethanol) before lysis. The cells were disrupted by sonication, and the supernatant was collected by centrifugation at 23,500 g for 60 min at 4 °C. The supernatant was mixed with the pre-equilibrated Ni–NTA affinity resin (Qiagen) at 4 °C for 1 h. The bound protein was washed with 10 column volumes of buffer A, and the target protein was then eluted with Ni-NTA buffer B, which contains the same components of buffer A plus 250 mM imidazole. The his6-tag at the N-terminus was cleaved off by treating with the PreScission protease overnight in the presence of 5 mM β-mercaptoethanol, and the reaction mix was subsequently applied onto a Histrap column (GE Healthcare) to remove uncut protein. The unbound portion was pooled, dialyzed to a buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM DTT for two hours. The protein was further concentrated to 10 mg/ml, then flash frozen in liquid nitrogen and stored at −80 °C.

All point mutations for RidA activity assays were created by QuikChange. The RidA-S68/pET28a (+) plasmid (the fragment represents residues S68–L187) was used as the template. All mutations were confirmed by DNA sequencing and the integrity of the expressed proteins was assayed by a Superdex 75 size-exclusion column. 10% (v/v) glycerol was added to the purified mutants before they were flash frozen. The cloning, expression and purification of *Arabidopsis thaliana* threonine dehydratase was described in a previous reference16.

### Crystallization and data collection.

Among the several constructs we tested, the RidA-S68 construct allowed us to produce diffracting crystals. Crystals were obtained using the sitting drop vapor diffusion method in a 96-well plate after ten days at 25 °C. The reservoir solution contains 18% PEG 3350, 0.1 M MES, pH 6.0. The crystals of RidA with ligand pyruvate were obtained by soaking the crystals of the apoprotein with 20 mM pyruvate for 1 hour. The best crystals were transferred to a cryo-protecinant solution (20% (v/v) glycerol plus the reservoir solution) and were flash frozen in liquid nitrogen. Native data for AtRidA in the apo form or in complex with ligand pyruvate and the pyruvate complex were collected.

| Crystals          | Apo-RidA (SHP7) | RidA-pyruvate complex (SHP6) |
|-------------------|----------------|-----------------------------|
| **Data collection** |                |                             |
| Wavelength (Å)    | 1.54 Å         | 1.54 Å                      |
| Space group       | H3             | P1                          |
| **Cell dimensions (Å)** |            |                             |
| a, b, c (Å)       | 76.9, 76.9, 40.3 | 40.3, 46.3, 46.4           |
| α, β, γ (°)       | 90.0, 90.0, 120.0 | 111.4, 107.7, 106.3        |
| Resolution (Å)    | 25.67–2.00      | 22.30–2.30                  |
| Rmerge            | 0.045 (0.183)   | 0.065 (0.276)               |
| Rfree             | 0.055 (0.227)   | 0.086 (0.374)               |
| CC1/2             | 0.998 (0.949)   | 0.997 (0.912)               |
| Wilson B          | 19.3           | 34.8                        |
| Rmerge/Rfree      | 0.153/0.212     | 0.204/0.238                 |
| **Refinement**    |                |                             |
| Resolution (Å)    | 25.67–2.00      | 22.30–2.30                  |
| No. reflections   | 5725            | 11771                       |
| Rmerge/Rfree      | 0.153/0.212     | 0.204/0.238                 |
| No. atoms         |                |                             |
| Protein           | 808             | 2424                        |
| Ligand            | —               | 18                          |
| Water molecules   | 85              | 36                          |
| B-factors (Å²)    |                |                             |
| protein           | 19.4            | 31.0                        |
| Ligand            | —               | 33.3                        |
| Water             | 30.7            | 31.3                        |
| R.m.s deviations  |                |                             |
| Bond lengths (Å)  | 0.016           | 0.003                       |
| Bond angles (°)   | 1.46            | 0.82                        |

Table 2. Data collection and refinement statistics. *b*Values in parentheses are for the highest-resolution shell.  
*Rmerge* = Σ[(I − <I>)/σ(I)], where I is the observed intensity.  
*Rfree* = Σ(|Fo| − |Fc|)/Σ|Fo|, calculated from working data set.  
*Rfactor* is calculated from 5.0% of data randomly chosen and not included in refinement.

---

The expression of RidA-S68 was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.2 mM, at 25 °C for 18 hours. Cells were harvested by centrifugation at 3,030 g for 20 min at 4 °C, and resuspended in pre-chilled nickel-nitrilotriacetic acid (Ni–NTA) buffer A (250 mM NaCl, 10 mM imidazole, 40 mM Tris-HCl, pH 8.0, 1 mM phenylmethlysulfonyl fluoride (PMSF) and 1 mM β-mercaptoethanol) before lysis. The cells were disrupted by sonication, and the supernatant was collected by centrifugation at 23,500 g for 60 min at 4 °C. The supernatant was mixed with the pre-equilibrated Ni–NTA affinity resin (Qiagen) at 4 °C for 1 h. The bound protein was washed with 10 column volumes of buffer A, and the target protein was then eluted with Ni–NTA buffer B, which contains the same components of buffer A plus 250 mM imidazole. The his6-tag at the N-terminus was cleaved off by treating with the PreScission protease overnight in the presence of 5 mM β-mercaptoethanol, and the reaction mix was subsequently applied onto a Histrap column (GE Healthcare) to remove uncut protein. The unbound portion was pooled, dialyzed to a buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and 1 mM DTT for two hours. The protein was further concentrated to 10 mg/ml, then flash frozen in liquid nitrogen and stored at −80 °C. All point mutations for RidA activity assays were created by QuikChange. The RidA-S68/pET28a (+) plasmid (the fragment represents residues S68–L187) was used as the template. All mutations were confirmed by DNA sequencing and the integrity of the expressed proteins was assayed by a Superdex 75 size-exclusion column. 10% (v/v) glycerol was added to the purified mutants before they were flash frozen. The cloning, expression and purification of *Arabidopsis thaliana* threonine dehydratase was described in a previous reference16.
with pyruvate were collected from frozen crystals at −173 °C using an in-house Oxford Diffraction Xcalibur Nova diffractometer. The data were processed and scaled using CrysAlisPro (v.1.171.3.49; Oxford Diffraction) and SCALA from the CCP4 suite.27 The space group of the crystals for apo protein was P21 and the crystal diffracted to 2.0 Å resolution with a completeness of 99.87%. Cell content analysis suggested that each asymmetric unit contains one monomer. To solve the structure, coordinates of a putative endoribonuclease (TM0215) structure (PDB entry 2B33) were used as the search model for molecular replacement. The initial model was extended by PHENIX using the autobuild option,26 and the resulting model was further built manually according to the electron-density map with Coot.27 Multiple cycles of refinement alternating with model rebuilding were carried out by REFMAC5.28 The R factor was 15.3% (Rfree = 21.2%) for the final model, which was validated by SFCHECK and Molprobity.29,30 The Ramachandran plots of the final models have 98.1%, 1.9%, 0% residues in the most favorable, generously allowed and disallowed region for the apoenzyme. The structure of the complex with pyruvate was solved using the apo protein structure and the space group was P1. The crystal diffracted to 2.3 Å resolution and each asymmetric unit contains three monomers. The R factor was 20.4% (Rfree = 23.8%) for the final model. The Ramachandran plots of the final models have 96.2%, 3.8%, 0% residues in the most favorable, generously allowed and disallowed region for the apoenzyme. The data collection and refinement statistics are listed in Table 2. All figures were produced with PyMOL (http://www.pymol.org). The secondary structure of RiaA-S668 was prepared by ESPript.31

Enzyme activity assays.

The activity assays followed a previous protocol described by Niehaus et al. Briefly, a 500-μL assay mixture contains 50 mM potassium pyrophosphate, pH 8.7, 10 mM semicarbazide-HCl (neutralized), 0.5 μM threonine dehydratase, and 10 μM of RibA. 2 mM L-Thr (final concentration) is added to the assay to start the reactions, and the absorbance values at the time point 90 s are used to calculate the relative activity with the formula: the relative activity = (Amean RibA − Amut)/(Aave RibA − ARibA WT) × 100%, where Amean RibA, ARibA, and ARibA WT are the absorbance values at 248 nm in the absence of the enzyme, in the presence of the RibA mutants and the RibA WT at the time point 90 s, respectively.

References

1. Goupil-Feuillerat, N., Cocaign-Bousquet, M., Godon, J. J., Ehrlich, S. D. & Renault, P. Dual role of alpha-acetolactate decarboxylase in Lactococcus lactis subsp. lactis. Journal of bacteriology 179, 6285–6293 (1997).
2. Asagi, K. et al. Purification, characterization and differentiation-dependent expression of a peroxilic acid soluble protein from rat kidney. Nephron 79, 80–90 (1998).
3. Oka, T. et al. Isolation and characterization of a novel peroxilic acid-soluble protein inhibiting cell-free protein synthesis. The Journal of biological chemistry 270, 30600–30607 (1995).
4. Enos-Berlage, J. L., Langendorf, M. J. & Downs, D. M. Complex metabolic phenotypes caused by a mutation in yjgF, encoding a member of the highly conserved YER057c/YjgF family of proteins. Journal of bacteriology 180, 6519–6528 (1998).
5. Schmitz, G. & Downs, D. M. Reduced transaminase B (LIVe) activity caused by the lack of yjgF is dependent on the status of threonine deaminase (LIVe) in Salmonella enterica serovar Typhimurium. Journal of bacteriology 186, 803–810 (2004).
6. Kim, J. M., Yoshikawa, H. & Shirahige, K. A member of the YER057c/YjgF family links isoleucine biosynthesis and intact mitochondria maintenance in Saccharomyces cerevisiae. Genes to cells : devoted to molecular & cellular mechanisms 6, 507–517 (2001).
7. Rappu, P., Shin, B. S., Zalkin, H. & Mantala, P. A role for a highly conserved protein of unknown function in regulation of Bacillus subtilis purA by the purine repressor. Journal of bacteriology 181, 3810–3815 (1999).
8. Lambrecht, J. A., Flynn, J. M. & Downs, D. M. Conserved YjgF protein family domainates reactive enamine/imine intermediates of pyridoxal 5′-phosphate (PLP)-dependent enzyme reactions. The Journal of biological chemistry 287, 3454–3461, doi: 10.1074/jbc.M111.304477 (2012).
9. Ueno, H., Nikos, J. J. & Metzler, D. E. Chemistry of the inactivation of cytosolic aspartate aminotransferase by serine O-sulfate. Biochemistry 21, 4387–4393 (1982).
10. Ueno, J. J., Ueno, H., Feldhaus, R. W. & Metzler, D. E. A novel reaction of the coenzyme of glutamate decarboxylase with L-serine O-sulfate. Biochemistry 21, 4377–4386 (1982).
11. Cooper, A. L. et al. Cysteine S-conjugate beta-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents. Amino acids 41, 7–27, doi: 10.1007/s00726-010-0552-0 (2011).
12. Lambrecht, J. A., Schmitz, G. E. & Downs, D. M. RdA proteins prevent metabolic damage inflicted by PLP-dependent dehydratases in all domains of life. mBio 4, e00333–00013, doi: 10.1128/mBio.00333-13 (2013).
13. Muller, A. et al. Activation of RdA chaperone function by N-chlorination. Nature communications 5, 5804, doi: 10.1038/ncomms6804 (2014).
14. Morishita, R. et al. Ribonuclease activity of rat liver peroxilic acid-soluble protein, a potent inhibitor of protein synthesis. The journal of biological chemistry 274, 20688–20692 (1999).
15. Leitner-Dalton, Y. et al. ChrD, a plant member of the evolutionarily conserved YfG family, influences photosynthesis and chloroplast morphogenesis. Planta 225, 89–102, doi: 10.1007/s00425-006-0332-y (2006).
16. Niehaus, T. D. et al. Arabidopsis and maize RdA proteins preempt reactive enamine/imine damage to branch-chain amino acid biosynthesis in plastids. The Plant cell 26, 3010–3022, doi: 10.1105/tpc.114.126854 (2014).
17. Niehaus, T. D. et al. Genomic and experimental evidence for multiple metabolic functions in the RdA/YfG/YER057c/UK114 (Rid) family protein. BMC genomics 16, 382, doi: 10.1186/s12864-015-1584-3 (2015).
18. Sinha, S. et al. Crystal structure of Bacillus subtilis Yabf, a purine regulatory protein and member of the highly conserved YrfG family. Proceedings of the National Academy of Sciences of the United States of America 96, 13074–13079 (1999).
19. Vola, K. A test case for structure-based functional assignment: the 1.2A crystal structure of the YrfG gene product from Escherichia coli. Protein science: a publication of the Protein Society 8, 2428–2437, doi: 10.1101/po.8.11.2428 (1999).
20. Maniisetty, B. A. et al. Crystal structure of Homo sapiens protein CYP4V5. Proteins 54, 797–800, doi: 10.1002/prot.10619 (2004).
21. Miyawaka, T. et al. Crystal structure of the YfG/YER057c/UK114 family protein from the hyperthermophilic archaeon Sulfolobus tokodaii strain 7. Proteins 62, 557–561, doi: 10.1002/prot.20778 (2006).
22. Burman, J. D., Stevenson, C. E., Sawers, R. G. & Lawson, D. M. The crystal structure of Escherichia coli ‘IdcF, a member of the highly conserved YfG/YER057c/UK114 family. BMC structural biology 7, 36, doi: 10.1186/1472-6807-7-30 (2007).
23. Deriu, D., Briand, C., Mistienn, E., Naktinis, V. & Grutter, M. G. Structure and oligomeric state of the mammalian tumour-associated antigen UK114. Acta crystallographica. Section D, Biological crystallography 59, 1676–1678 (2003).
24. Hafner, E. W. & Wellner, D. Reactivity of the imino acids formed in the amino acid oxidase reaction. *Biochemistry* **18**, 411–417 (1979).

25. Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta crystallographica. Section D, Biological crystallography* **67**, 235–242, doi: 10.1107/s0907444910045749 (2011).

26. Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**, 213–221, doi: 10.1107/s0907444909052925 (2010).

27. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta crystallographica. Section D, Biological crystallography* **66**, 486–501, doi: 10.1107/s0907444910007493 (2010).

28. Murshudov, G. N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures. *Acta crystallographica. Section D, Biological crystallography* **67**, 235–242, doi: 10.1107/s0907444911001314 (2011).

29. Vaguine, A. A., Richelle, J. & Wodak, S. J. SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. *Acta crystallographica. Section D, Biological crystallography* **55**, 191–205, doi: 10.1107/s090744499802684 (1999).

30. Chen, V. B. *et al.* MolProbity: all-atom structure validation for macromolecular crystallography. *Acta crystallographica. Section D, Biological crystallography* **66**, 12–21, doi: 10.1107/s0907444999042073 (2010).

31. Gouet, P., Robert, X. & Courcelle, E. ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins. *Nucleic acids research* **31**, 3320–3323 (2003).

Acknowledgements

This work was supported by Science and Technology Program of Guangzhou 201504010025, Guangdong Innovative Research Team Program NO. 2011Y038, and the Fundamental Research Funds for the Central Universities 15lgjc15.

Author Contributions

W.X. conceived and designed research; X.L., J.Z. and X.C. performed research; W.X. analyzed data and wrote the paper. All authors reviewed the manuscript.

Additional Information

Accession codes: The atomic coordinates and structure factors have been deposited in the Protein Data Bank with accession numbers 5HP7 and 5HP8 for the apo and complex structure of AtRidA respectively.

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liu, X. *et al.* Crystal structures of RidA, an important enzyme for the prevention of toxic side products. *Sci. Rep.* **6**, 30494; doi: 10.1038/srep30494 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016